Reactive oxygen species (ROS) play both positive and negative roles in the proliferation and survival of a cell. This dual nature has been exploited by leukemia cells to promote growth, survival, and genomic instability—some of the hallmarks of the cancer phenotype. In addition to altered ROS levels, many antioxidants are dysregulated in leukemia cells. Together, the production of ROS and the expression and activity of antioxidant enzymes make up the primary redox control of leukemia cells. By manipulating this system, leukemia cells gain proliferative and survival advantages, even in the face of therapeutic insults. Standard treatment options have improved leukemia patient survival rates in recent years, although relapse and the development of resistance are persistent challenges. Therapies targeting the redox environment show promise for these cases. This review highlights the molecular mechanisms that control the redox milieu of leukemia cells. In particular, ROS production by the mitochondrial electron transport chain, NADPH oxidase, xanthine oxidoreductase, and cytochrome P450 will be addressed. Expression and activation of antioxidant enzymes such as superoxide dismutase, catalase, heme oxygenase, glutathione, thioredoxin, and peroxiredoxin are perturbed in leukemia cells, and the functional consequences of these molecular alterations will be described. Lastly, we delve into how these pathways can be potentially exploited therapeutically to improve treatment regimens and promote better outcomes for leukemia patients. Antioxid. Redox Signal. 18, 1349–1383.
AdamsJ, PalombellaVJ, ElliottPJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs, 18:109–121. 2000.
2.
AdamsJM, CoryS. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26:1324–1337. 2007.
3.
Agrawal-SinghS, IskenF, AgelopoulosK, KleinHU, ThoennissenNH, KoehlerG, HascherA, BaumerN, BerdelWE, ThiedeC, EhningerG, BeckerA, SchlenkeP, WangY, McClellandM, KrugU, KoschmiederS, BuchnerT, YuDY, SinghSV, HansenK, ServeH, DugasM, Muller-TidowC. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood, 119:2346–2357. 2012.
4.
AgrawalSG, LiuFT, WisemanC, ShiraliS, LiuH, LillingtonD, DuMQ, Syndercombe-CourtD, NewlandAC, GribbenJG, JiaL. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood, 111:2790–2796. 2008.
5.
AlamJ. Multiple elements within the 5′ distal enhancer of the mouse heme oxygenase-1 gene mediate induction by heavy metals. J Biol Chem, 269:25049–25056. 1994.
6.
AlamJ, CamhiS, ChoiAM. Identification of a second region upstream of the mouse heme oxygenase-1 gene that functions as a basal level and inducer-dependent transcription enhancer. J Biol Chem, 270:11977–11984. 1995.
7.
AldieriE, RigantiC, PolimeniM, GazzanoE, LussianaC, CampiaI, GhigoD. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab, 9:686–696. 2008.
8.
Antico ArciuchVG, ElgueroME, PoderosoJJ, CarrerasMC. Mitochondrial regulation of cell cycle and proliferation. Antioxid Redox Signal, 16:1150–1180. 2012.
9.
BakerA, PayneCM, BriehlMM, PowisG. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res, 57:5162–5167. 1997.
10.
BalabanRS, NemotoS, FinkelT. Mitochondria, oxidants, and aging. Cell, 120:483–495. 2005.
11.
BalisFM, HolcenbergJS, ZimmS, TubergenD, CollinsJM, MurphyRF, GilchristGS, HammondD, PoplackDG. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther, 41:384–387. 1987.
12.
BanK, GaoY, AminHM, HowardA, MillerC, LinQ, LengX, MunsellM, Bar-EliM, ArlinghausRB, ChandraJ. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood, 111:2904–2908. 2008.
13.
BarananoDE, RaoM, FerrisCD, SnyderSH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A, 99:16093–16098. 2002.
14.
BattistiV, MadersLD, BagatiniMD, SantosKF, SpanevelloRM, MaldonadoPA, BruleAO, Araujo MdoC, SchetingerMR, MorschVM. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem, 41:511–518. 2008.
15.
BedardK, KrauseKH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 87:245–313. 2007.
16.
BezerraDP, MilitaoGC, de CastroFO, PessoaC, de MoraesMO, SilveiraER, LimaMA, ElmiroFJ, Costa-LotufoLV. Piplartine induces inhibition of leukemia cell proliferation triggering both apoptosis and necrosis pathways. Toxicol In Vitro, 21:1–8. 2007.
17.
BhandarkarSS, JaconiM, FriedLE, BonnerMY, LefkoveB, GovindarajanB, PerryBN, ParharR, MackelfreshJ, SohnA, StouffsM, KnausU, YancopoulosG, ReissY, BenestAV, AugustinHG, ArbiserJL. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest, 119:2359–2365. 2009.
18.
BiaglowJE, MillerRA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther, 4:6–13. 2005.
19.
BishopJF, MatthewsJP, YoungGA, SzerJ, GillettA, JoshuaD, BradstockK, EnnoA, WolfMM, FoxR, CobcroftR, HerrmannR, Van Der WeydenM, LowenthalRM, PageF, GarsonOM, JunejaS. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87:1710–1717. 1996.
20.
BiswasS, ZhaoX, MoneAP, MoX, VargoM, JarjouraD, ByrdJC, MuthusamyN. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res, 34:925–931. 2010.
21.
BorchmannP, HubelK, SchnellR, EngertA. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther, 35:80–83. 1997.
22.
BowenDT, FrewME, HillsR, GaleRE, WheatleyK, GrovesMJ, LangabeerSE, KottaridisPD, MoormanAV, BurnettAK, LinchDC. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood, 106:2113–2119. 2005.
23.
BradburyCA, KhanimFL, HaydenR, BunceCM, WhiteDA, DraysonMT, CraddockC, TurnerBM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 19:1751–1759. 2005.
24.
BrandMD. The sites and topology of mitochondrial superoxide production. Exp Gerontol, 45:466–472. 2010.
25.
BraunBS, ShannonK. Targeting Ras in myeloid leukemias. Clin Cancer Res, 14:2249–2252. 2008.
26.
ButlerLM, ZhouX, XuWS, ScherHI, RifkindRA, MarksPA, RichonVM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A, 99:11700–11705. 2002.
27.
ButterfieldLH, MerinoA, GolubSH, ShauH. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal, 1:385–402. 1999.
28.
CalvertP, YaoKS, HamiltonTC, O'DwyerPJ. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact, 111–112:213–224. 1998.
29.
CaoC, LengY, HuangW, LiuX, KufeD. Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem, 278:39609–39614. 2003.
30.
CarewJS, HuangP. Mitochondrial defects in cancer. Mol Cancer, 1:9. 2002.
31.
CarewJS, NawrockiST, KahueCN, ZhangH, YangC, ChungL, HoughtonJA, HuangP, GilesFJ, ClevelandJL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood, 110:313–322. 2007.
32.
CarewJS, NawrockiST, XuRH, DunnerK, McConkeyDJ, WierdaWG, KeatingMJ, HuangP. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia, 18:1934–1940. 2004.
33.
CarewJS, ZhouY, AlbitarM, CarewJD, KeatingMJ, HuangP. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia, 17:1437–1447. 2003.
34.
CelikH, ArincE. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect. J Pharm Sci, 11:68–82. 2008.
35.
ChadaS, WhitneyC, NewburgerPE. Post-transcriptional regulation of glutathione peroxidase gene expression by selenium in the HL-60 human myeloid cell line. Blood, 74:2535–2541. 1989.
36.
ChanYR, ZanettiM, GennaroR, GalloRL. Anti-microbial activity and cell binding are controlled by sequence determinants in the anti-microbial peptide PR-39. J Invest Dermatol, 116:230–235. 2001.
37.
ChandraJ, HackbarthJ, LeS, LoegeringD, BoneN, BruzekLM, NarayananVL, AdjeiAA, KayNE, TefferiA, KarpJE, SausvilleEA, KaufmannSH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood, 102:4512–4519. 2003.
38.
ChauhanPS, IhsanR, YadavDS, MishraAK, BhushanB, SoniA, KaushalM, DeviTR, SalujaS, GuptaDK, MittalV, SaxenaS, KapurS. Association of glutathione S-transferase, EPHX, and p53 codon 72 gene polymorphisms with adult acute myeloid leukemia. DNA Cell Biol, 30:39–46. 2011.
39.
ChelikaniP, FitaI, LoewenPC. Diversity of structures and properties among catalases. Cell Mol Life Sci, 61:192–208. 2004.
ChenKS, HsiaoYC, KuoDY, ChouMC, ChuSC, HsiehYS, LinTH. Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells. Leuk Res, 33:297–307. 2009.
42.
ChenMB, ShenWX, YangY, WuXY, GuJH, LuPH. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Phys, 226:1915–1925. 2011.
43.
ChenSJ, ZhouGB, ZhangXW, MaoJH, de TheH, ChenZ. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 117:6425–6437. 2011.
44.
ChenYR, WangW, KongAN, TanTH. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem, 273:1769–1775. 1998.
45.
ChouWC, JieC, KenedyAA, JonesRJ, TrushMA, DangCV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A, 101:4578–4583. 2004.
46.
ChoudharyC, KumarC, GnadF, NielsenML, RehmanM, WaltherTC, OlsenJV, MannM. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325:834–840. 2009.
47.
ChungE, KondoM. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res, 49:248–268. 2011.
48.
ChungFL, MorseMA, EklindKI, LewisJ. Quantitation of human uptake of the anticarcinogen phenethyl isothiocyanate after a watercress meal. Cancer Epidemiol Biomarkers Prev, 1:383–388. 1992.
49.
CoeE, SchimmerAD. Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma, 49:1976–1981. 2008.
50.
ColletJF, MessensJ. Structure, function, and mechanism of thioredoxin proteins. Antioxid Redox Signal, 13:1205–1216. 2010.
51.
ConawayCC, YangYM, ChungFL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab, 3:233–255. 2002.
52.
ConradM, JakupogluC, MorenoSG, LipplS, BanjacA, SchneiderM, BeckH, HatzopoulosAK, JustU, SinowatzF, SchmahlW, ChienKR, WurstW, BornkammGW, BrielmeierM. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol, 24:9414–9423. 2004.
53.
DasmahapatraG, NguyenTK, DentP, GrantS. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res, 30:1263–1272. 2006.
54.
DasmahapatraG, RahmaniM, DentP, GrantS. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood, 107:232–240. 2006.
55.
DeiningerMW, GoldmanJM, MeloJV. The molecular biology of chronic myeloid leukemia. Blood, 96:3343–3356. 2000.
56.
DokmanovicM, ClarkeC, MarksPA. Histone deacetylase inhibitors: overview and perspectives. Mol Can Res, 5:981–989. 2007.
57.
DoroshowJH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun, 135:330–335. 1986.
58.
DoroshowJH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci U S A, 83:4514–4518. 1986.
59.
DownwardJ. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer, 3:11–22. 2003.
60.
DuechlerM, LinkeA, CebulaB, ShehataM, SchwarzmeierJD, RobakT, SmolewskiP. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol, 74:407–417. 2005.
61.
ErTK, TsaiSM, WuSH, ChiangW, LinHC, LinSF, TsaiLY, LiuTZ. Antioxidant status and superoxide anion radical generation in acute myeloid leukemia. Clin Biochem, 40:1015–1019. 2007.
62.
ErkelandSJ, PalandeKK, ValkhofM, GitsJ, Danen-van OorschotA, TouwIP. The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients. Leuk Res, 33:1367–1371. 2009.
63.
FaderlS, RaiK, GribbenJ, ByrdJC, FlinnIW, O'BrienS, ShengS, EsseltineDL, KeatingMJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer, 107:916–924. 2006.
64.
FaheyJW, ZalcmannAT, TalalayP. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry, 56:5–51. 2001.
65.
FaheyJW, ZhangY, TalalayP. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A, 94:10367–10372. 1997.
66.
FangJ, SekiT, MaedaH. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev, 61:290–302. 2009.
67.
FarberCM, KanganisDN, LiebesLF, SilberR. Antioxidant enzymes in lymphocytes from normal subjects and patients with chronic lymphocytic leukaemia: increased glutathione peroxidase activity in CLL B lymphocytes. Br J Haematol, 72:32–35. 1989.
68.
FerND, ShoemakerRH, MonksA. Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. J Exp Clin Cancer Res, 29:91. 2010.
69.
FerrarisAM, RolfoM, MangeriniR, GaetaniGF. Increased glutathione in chronic lymphocytic leukemia lymphocytes. Am J Hematol, 47:237–238. 1994.
FinkelT. Signal transduction by reactive oxygen species. J Cell Biol, 194:7–15. 2011.
72.
FribleyA, ZengQ, WangCY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol, 24:9695–9704. 2004.
73.
FukaiT, Ushio-FukaiM. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal, 15:1583–1606. 2011.
74.
FurusawaS, KimuraE, KisaraS, NakanoS, MurataR, TanakaY, SakaguchiS, TakayanagiM, TakayanagiY, SasakiK. Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull, 24:474–479. 2001.
75.
GaoN, BudhrajaA, ChengS, LiuEH, ChenJ, YangZ, ChenD, ZhangZ, ShiX. Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways. Cell Death Dis, 2:e140. 2011.
76.
GaoS, MobleyA, MillerC, BoklanJ, ChandraJ. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res, 32:771–780. 2008.
77.
GaoY, HowardA, BanK, ChandraJ. Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells. J Biol Chem, 284:7114–7125. 2009.
78.
Garcia-ManeroG, YangH, Bueso-RamosC, FerrajoliA, CortesJ, WierdaWG, FaderlS, KollerC, MorrisG, RosnerG, LobodaA, FantinVR, RandolphSS, HardwickJS, ReillyJF, ChenC, RickerJL, SecristJP, RichonVM, FrankelSR, KantarjianHM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111:1060–1066. 2008.
79.
GattermannN. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res, 24:141–151. 2000.
80.
GewirtzDA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol, 57:727–741. 1999.
81.
GibbsBF, YasinskaIM, OnikuAE, SumbayevVV. Effects of stem cell factor on hypoxia-inducible factor 1 alpha accumulation in human acute myeloid leukaemia and LAD2 mast cells. PLoS One, 6:e22502. 2011.
82.
GillilandDG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol, 39:6–11. 2002.
83.
GleixnerKV, MayerhoferM, ValesA, GruzeA, HormannG, Cerny-ReitererS, LacknerE, HadzijusufovicE, HerrmannH, IyerAK, KrauthMT, PicklWF, MarianB, Panzer-GrumayerR, SillaberC, MaedaH, ZielinskiC, ValentP. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr Cancer Drug Targets, 9:675–689. 2009.
GoodmanJ, HochsteinP. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun, 77:797–803. 1977.
86.
GriffithsSD, BurthemJ, UnwinRD, HolyoakeTL, MeloJV, LucasGS, WhettonAD. The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol, 36:81–89. 2007.
87.
GroningerE, Meeuwsen-De BoerGJ, De GraafSS, KampsWA, De BontES. Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?Int J Oncol, 21:1339–1345. 2002.
88.
GuzmanML, JordanCT. Feverfew: weeding out the root of leukaemia. Expert Opin Biol Ther, 5:1147–1152. 2005.
89.
GuzmanML, RossiRM, KarnischkyL, LiX, PetersonDR, HowardDS, JordanCT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 105:4163–4169. 2005.
HaberDA, SettlemanJ. Cancer: drivers and passengers. Nature, 446:145–146. 2007.
92.
HachiyaM, AkashiM. Catalase regulates cell growth in HL60 human promyelocytic cells: evidence for growth regulation by H(2)O(2)Radiat Res, 163:271–282. 2005.
93.
HadzijusufovicE, RebuzziL, GleixnerKV, FerencV, PeterB, KondoR, GruzeA, KneidingerM, KrauthMT, MayerhoferM, SamorapoompichitP, GreishK, IyerAK, PicklWF, MaedaH, WillmannM, ValentP. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. Exp Hematol, 36:1461–1470. 2008.
94.
HanadaM, DeliaD, AielloA, StadtmauerE, ReedJC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood, 82:1820–1828. 1993.
95.
HayesJD, McMahonM, ChowdhryS, Dinkova-KostovaAT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal, 13:1713–1748. 2010.
96.
HeL, LuoL, ProctorSJ, MiddletonPG, BlakelyEL, TaylorRW, TurnbullDM. Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia, 17:2487–2491. 2003.
97.
HeasmanSA, ZaitsevaL, BowlesKM, RushworthSA, MacewanDJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget, 2:658–668. 2011.
98.
HeasmanSJ, RidleyAJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol, 9:690–701. 2008.
99.
HechtSS. Chemoprevention by isothiocyanates. J Cell Biochem Suppl, 22:195–209. 1995.
100.
HechtSS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev, 32:395–411. 2000.
101.
HedleyDW, McCullochEA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2. Leukemia, 10:1143–1149. 1996.
102.
HershkoA. Ubiquitin: roles in protein modification and breakdown. Cell, 34:11–12. 1983.
103.
HolePS, DarleyRL, TonksA. Do reactive oxygen species play a role in myeloid leukemias?Blood, 117:5816–5826. 2011.
104.
HolePS, PearnL, TonksAJ, JamesPE, BurnettAK, DarleyRL, TonksA. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood, 115:1238–1246. 2010.
105.
HortonTM, PatiD, PlonSE, ThompsonPA, BomgaarsLR, AdamsonPC, IngleAM, WrightJ, BrockmanAH, PatonM, BlaneySM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res, 13:1516–1522. 2007.
106.
HowardAN, BridgesKA, MeynRE, ChandraJ. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. Cancer Chemother Pharmacol, 65:41–54. 2009.
107.
HowladerN, NooneAM, KrapchoM, NeymanN, AminouR, AltekruseSF, KosaryCL, RuhlJ, TatalovichZ, ChoH, MariottoA, EisnerMP, LewisDR, ChenHS, FeuerEJ, CroninKA. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 1975–2009. http://seer.cancer.gov/csr/1975_2009_pops09/based on November 2011 SEER data submission, posted to the SEER web site2012.
108.
HuY, LuW, ChenG, ZhangH, JiaY, WeiY, YangH, ZhangW, FiskusW, BhallaK, KeatingM, HuangP, Garcia-ManeroG. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood, 116:2732–2741. 2010.
109.
HuangP, FengL, OldhamEA, KeatingMJ, PlunkettW. Superoxide dismutase as a target for the selective killing of cancer cells. Nature, 407:390–395. 2000.
110.
IacobiniM, MenichelliA, PalumboG, MultariG, WernerB, Del PrincipeD. Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells. Biochem Pharmacol, 61:1033–1040. 2001.
111.
IrwinME, SinghM, ChandraJ. Targeting of Fyn induction by oxidative stress is an effective strategy for overcoming kinase inhibitor resistance in chronic myeloid leukemia and treating blast crisis [abstract]AACR: New Horizons in Cancer Research Biology to Prevention to Therapy. Gurgaon: Delhi, India, 2011.
112.
IshikawaM, NumazawaS, YoshidaT. Redox regulation of the transcriptional repressor Bach1. Free Radic Biol Med, 38:1344–1352. 2005.
113.
ItoK, HiraoA, AraiF, TakuboK, MatsuokaS, MiyamotoK, OhmuraM, NakaK, HosokawaK, IkedaY, SudaT. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med, 12:446–451. 2006.
114.
JenkinsC, HewamanaS, GilkesA, NeelakantanS, CrooksP, MillsK, PepperC, BurnettA. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol, 143:661–671. 2008.
115.
JensenKS, HansenRE, WintherJR. Kinetic and thermodynamic aspects of cellular thiol-disulfide redox regulation. Antioxid Redox Signal, 11:1047–1058. 2009.
JohnsonCR, ChunJ, BittmanR, JarvisWD. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells. J Pharmacol Exp Ther, 309:452–461. 2004.
118.
JoncourtF, Oberli-SchrammliAE, StadlerM, BuserK, FransciniL, FeyMF, CernyT. Patterns of drug resistance parameters in adult leukemia. Leuk Lymphoma, 17:101–109. 1995.
119.
KaminskiM, KiesslingM, SussD, KrammerPH, GulowK. Novel role for mitochondria: protein kinase Cθ–dependent oxidative signaling organelles in activation-induced T-cell death. Mol Cell Biol, 27:3625–3639. 2007.
120.
KannoS, HigurashiA, WatanabeY, ShoujiA, AsouK, IshikawaM. Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett, 152:149–158. 2004.
121.
KatoS, BowmanED, HarringtonAM, BlomekeB, ShieldsPG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst, 87:902–907. 1995.
122.
KearnsPR, PietersR, RottierMM, PearsonAD, HallAG. Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood, 97:393–398. 2001.
123.
KellyLM, GillilandDG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet, 3:179–198. 2002.
124.
KimJA, NeupaneGP, LeeES, JeongBS, ParkBC, ThapaP. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat, 21:1147–1158. 2011.
125.
KimJH, ChuSC, GramlichJL, PrideYB, BabendreierE, ChauhanD, SalgiaR, PodarK, GriffinJD, SattlerM. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood, 105:1717–1723. 2005.
126.
KimYR, EomJI, KimSJ, JeungHK, CheongJW, KimJS, MinYH. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther, 335:389–400. 2010.
127.
KindlerT, LipkaDB, FischerT. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 116:5089–5102. 2010.
128.
KondoR, GleixnerKV, MayerhoferM, ValesA, GruzeA, SamorapoompichitP, GreishK, KrauthMT, AichbergerKJ, PicklWF, EsterbauerH, SillaberC, MaedaH, ValentP. Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood, 110:661–669. 2007.
129.
KoopDR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J, 6:724–730. 1992.
KoptyraM, FalinskiR, NowickiMO, StoklosaT, MajsterekI, Nieborowska-SkorskaM, BlasiakJ, SkorskiT. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood, 108:319–327. 2006.
132.
KornblauSM, ThallPF, EstrovZ, WalterscheidM, PatelS, TheriaultA, KeatingMJ, KantarjianH, EsteyE, AndreeffM. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res, 5:1758–1766. 1999.
133.
KosZ, PavelicL, PekicB, PavelicK. Reversal of human myeloid leukemia cells into normal granulocytes and macrophages: activity and intracellular distribution of catalase. Oncology, 44:245–247. 1987.
134.
KrajinovicM, LabudaD, RicherC, KarimiS, SinnettD. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood, 93:1496–1501. 1999.
135.
KrajinovicM, SinnettH, RicherC, LabudaD, SinnettD. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer, 97:230–236. 2002.
136.
KrishnaS, LowIC, PervaizS. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J, 435:545–551. 2011.
137.
KurzrockR, KantarjianHM, DrukerBJ, TalpazM. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med, 138:819–830. 2003.
138.
KweeJK, LuqueDG, FerreiraAC, VasconcelosFC, SilvaKL, KlumbCE, MaiaRC. Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anticancer Drugs, 19:975–981. 2008.
139.
LagadinouE, CallahanK, NeeringSJ, PeiS, MinhajuddinM, RossiRM, GroseV, CorbettC, BalysM, BrookesP, JordanCT. Reactive oxygen species (ROS) levels define functional heterogeneity in human leukemia stem cells and represent a critical parameter for therapeutic targeting [abstract]American Society of Hematology. San Diego, CA: Blood, 2011.
140.
LapperreTS, JimenezLA, AntonicelliF, DrostEM, HiemstraPS, StolkJ, MacNeeW, RahmanI. Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. FEBS Lett, 443:235–239. 1999.
141.
LeSB, HailerMK, BuhrowS, WangQ, FlattenK, PediaditakisP, BibleKC, LewisLD, SausvilleEA, PangYP, AmesMM, LemastersJJ, HolmuhamedovEL, KaufmannSH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem, 282:8860–8872. 2007.
142.
LeeSJ, YounYC, HanES, LeeCS. Depressant effect of mitochondrial respiratory complex inhibitors on proteasome inhibitor-induced mitochondrial dysfunction and cell death in PC12 cells. Neurochem Res, 30:1191–1200. 2005.
143.
LeeTC, ChengIC, ShueJJ, WangTC. Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells. Toxicol Appl Pharmacol, 250:69–77. 2011.
144.
LiQ, GuoY, OuQ, CuiC, WuWJ, TanW, ZhuX, LancetaLB, SanganalmathSK, DawnB, ShinmuraK, RokoshGD, WangS, BolliR. Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway. Circulation, 120:1222–1230. 2009.
145.
LilienthalN, PrinzC, Peer-ZadaAA, DoeringM, BaLA, HallekM, JacobC, HerlingM. Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic “sensor/effector” compounds. Leuk Lymphoma, 52:1407–1411. 2011.
146.
LingYH, LiebesL, ZouY, Perez-SolerR. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem, 278:33714–33723. 2003.
147.
LiuJJ, LiuQ, WeiHL, YiJ, ZhaoHS, GaoLP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Die Pharmazie, 66:440–444. 2011.
148.
LiuY, LiangY, ZhengT, YangG, ZhangX, SunZ, ShiC, ZhaoS. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J Neurooncol, 104:449–458. 2011.
149.
Lopez-PedreraC, VillalbaJM, SiendonesE, BarbarrojaN, Gomez-DiazC, Rodriguez-ArizaA, BuendiaP, TorresA, VelascoF. Proteomic analysis of acute myeloid leukemia: identification of potential early biomarkers and therapeutic targets. Proteomics 6 Suppl, 1:S293–S299. 2006.
150.
LowenbergB, PabstT, VellengaE, van PuttenW, SchoutenHC, GrauxC, FerrantA, SonneveldP, BiemondBJ, GratwohlA, de GreefGE, VerdonckLF, SchaafsmaMR, GregorM, TheobaldM, SchanzU, MaertensJ, OssenkoppeleGJ. Cytarabine dose for acute myeloid leukemia. N Engl J Med, 364:1027–1036. 2011.
151.
LuJ, ChewEH, HolmgrenA. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A, 104:12288–12293. 2007.
152.
LuX, HowardA, GaoY, SinghM, ChandraJ. Requirement for the Src family kinase, Fyn, in proliferation of BCR-ABL1 transduced bone marrow and aneuploidy in CML [abstract]AACR Annual Meeting, Washington D.C, 2010.
MalaiseM, SteinbachD, CorbaciogluS. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep, 4:77–82. 2009.
155.
MaraldiT, PrataC, Vieceli Dalla SegaF, CalicetiC, ZamboninL, FiorentiniD, HakimG. NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res, 43:1111–1121. 2009.
156.
MargoliashE, NovogrodskyA. A study of the inhibition of catalase by 3-amino-1:2:4:-triazole. Biochem J, 68:468–475. 1958.
157.
MargoliashE, NovogrodskyA, SchejterA. Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem J, 74:339–348. 1960.
158.
MarksPA, BreslowR. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol, 25:84–90. 2007.
159.
MartelliAM, EvangelistiC, ChappellW, AbramsSL, BaseckeJ, StivalaF, DoniaM, FagoneP, NicolettiF, LibraM, RuvoloV, RuvoloP, KempfCR, SteelmanLS, McCubreyJA. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 25:1064–1079. 2011.
160.
MasdehorsP, Merle-BeralH, MagdelenatH, DelicJ. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma, 38:499–504. 2000.
161.
MauBL, PowisG. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol, 43:1621–1627. 1992.
162.
MaungZT, HogarthL, ReidMM, ProctorSJ, HamiltonPJ, HallAG. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia. Leukemia, 8:1487–1491. 1994.
163.
MayerhoferM, FlorianS, KrauthMT, AichbergerKJ, BilbanM, MarculescuR, PrintzD, FritschG, WagnerO, SelzerE, SperrWR, ValentP, SillaberC. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res, 64:3148–3154. 2004.
164.
MayerhoferM, GleixnerKV, MayerhoferJ, HoermannG, JaegerE, AichbergerKJ, OttRG, GreishK, NakamuraH, DerdakS, SamorapoompichitP, PicklWF, SexlV, EsterbauerH, SchwarzingerI, SillaberC, MaedaH, ValentP. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood, 111:2200–2210. 2008.
165.
McHaleCM, ZhangL, SmithMT. Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. Carcinogenesis, 33:240–252. 2012.
166.
MeisterA, AndersonME. Glutathione. Annu Rev Biochem, 52:711–760. 1983.
167.
MenseSM, ZhangL. Heme: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases. Cell Res, 16:681–692. 2006.
168.
MillerCP, BanK, DujkaME, McConkeyDJ, MunsellM, PalladinoM, ChandraJ. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 110:267–277. 2007.
169.
MillerWHJr., SchipperHM, LeeJS, SingerJ, WaxmanS. Mechanisms of action of arsenic trioxide. Cancer Res, 62:3893–3903. 2002.
170.
MinottiG, MennaP, SalvatorelliE, CairoG, GianniL. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev, 56:185–229. 2004.
171.
MinucciS, NerviC, Lo CocoF, PelicciPG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?Oncogene, 20:3110–3115. 2001.
172.
MiyazakiT, KirinoY, TakenoM, SamukawaS, HamaM, TanakaM, YamajiS, UedaA, TomitaN, FujitaH, IshigatsuboY. Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci, 101:1409–1416. 2010.
173.
MurgoAJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6 Suppl, 2:22–28. 2001.
NakamuraH. Thioredoxin as a key molecule in redox signaling. Antioxid Redox Signal, 6:15–17. 2004.
176.
NakamuraH, FangJ, GahininathB, TsukigawaK, MaedaH. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J Control Release, 155:367–375. 2011.
177.
NakamuraH, MasutaniH, YodoiJ. Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Semin Cancer Biol, 16:444–451. 2006.
178.
NaughtonR, QuineyC, TurnerSD, CotterTG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia, 23:1432–1440. 2009.
179.
NebertDW, RussellDW. Clinical importance of the cytochromes P450. Lancet, 360:1155–1162. 2002.
180.
NguyenT, DaiY, AttkissonE, KramerL, JordanN, NguyenN, KolluriN, MuschenM, GrantS. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res, 17:3219–3232. 2011.
181.
NigroP, Dal PiazF, GallottaD, De TommasiN, BelisarioMA. Inhibition of the thioredoxin system is a basis for the antileukemic potential of 13-hydroxy-15-oxo-zoapatlin. Free Radic Biol Med, 45:875–884. 2008.
NishinakaY, NishiyamaA, MasutaniH, OkaS, AhsanKM, NakayamaY, IshiiY, NakamuraH, MaedaM, YodoiJ. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res, 64:1287–1292. 2004.
184.
NishiuraT, SuzukiK, KawaguchiT, NakaoH, KawamuraN, TaniguchiM, KanayamaY, YonezawaT, IizukaS, TaniguchiN. Elevated serum manganese superoxide dismutase in acute leukemias. Cancer Lett, 62:211–215. 1992.
185.
NowickiMO, FalinskiR, KoptyraM, SlupianekA, StoklosaT, GlocE, Nieborowska-SkorskaM, BlasiakJ, SkorskiT. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood, 104:3746–3753. 2004.
186.
OlmE, Jonsson-VidesaterK, Ribera-CortadaI, FernandesAP, ErikssonLC, LehmannS, RundlofAK, PaulC, BjornstedtM. Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett, 282:116–123. 2009.
187.
OltraAM, CarbonellF, TormosC, IradiA, SaezGT. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med, 30:1286–1292. 2001.
188.
OrsolicN, GolemovicM, Quintas-CardamaA, ScappiniB, ManshouriT, ChandraJ, BasicI, GilesF, KantarjianH, VerstovsekS. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci, 97:952–960. 2006.
189.
OzakiK, KosugiM, BabaN, FujioK, SakamotoT, KimuraS, TanimuraS, KohnoM. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun, 391:1610–1615. 2010.
190.
PalandeKK, BeekmanR, van der MeerenLE, BeverlooHB, ValkPJ, TouwIP. The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia. PloS One, 6:e16340. 2011.
191.
PanSS, PedersenL, BachurNR. Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption. Mol Pharmacol, 19:184–186. 1981.
192.
PaniG, BedogniB, AnzevinoR, ColavittiR, PalazzottiB, BorrelloS, GaleottiT. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res, 60:4654–4660. 2000.
193.
PapadopoulouLC, TheophilidisG, ThomopoulosGN, TsiftsoglouAS. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem Pharmacol, 57:481–489. 1999.
194.
PazhanisamySK, LiH, WangY, Batinic-HaberleI, ZhouD. NADPH oxidase inhibition attenuates total body irradiation-induced haematopoietic genomic instability. Mutagenesis, 26:431–435. 2011.
195.
PeiXY, DaiY, GrantS. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res, 10:3839–3852. 2004.
196.
PelicanoH, FengL, ZhouY, CarewJS, HilemanEO, PlunkettW, KeatingMJ, HuangP. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem, 278:37832–37839. 2003.
197.
PentaJS, JohnsonFM, WachsmanJT, CopelandWC. Mitochondrial DNA in human malignancy. Mutat Res, 488:119–133. 2001.
198.
Perez-GalanP, RoueG, VillamorN, MontserratE, CampoE, ColomerD. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107:257–264. 2006.
199.
PerryBN, GovindarajanB, BhandarkarSS, KnausUG, ValoM, SturkC, CarrilloCO, SohnA, CerimeleF, DumontD, LoskenA, WilliamsJ, BrownLF, TanX, IoffeE, YancopoulosGD, ArbiserJL. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol, 126:2316–2322. 2006.
200.
PiccoliC, RipoliM, ScrimaR, StanzialeP, Di IanniM, MorettiL, BiscottiniB, CarellaM, BoffoliD, TabilioA, CapitanioN. MtDNA mutation associated with mitochondrial dysfunction in megakaryoblastic leukaemic cells. Leukemia, 22:1938–1941. 2008.
201.
PotmesilM, IsraelM, SilberR. Two mechanisms of adriamycin-DNA interaction in L1210 cells. Biochem Pharmacol, 33:3137–3142. 1984.
202.
PowisG, MontfortWR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol, 41:261–295. 2001.
203.
PuiCH, EvansWE. Treatment of acute lymphoblastic leukemia. N Engl J Med, 354:166–178. 2006.
204.
Quillet-MaryA, JaffrezouJP, MansatV, BordierC, NavalJ, LaurentG. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem, 272:21388–21395. 1997.
205.
RahmanI, BiswasSK, JimenezLA, TorresM, FormanHJ. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid Redox Signal, 7:42–59. 2005.
206.
RajL, IdeT, GurkarAU, FoleyM, SchenoneM, LiX, TollidayNJ, GolubTR, CarrSA, ShamjiAF, SternAM, MandinovaA, SchreiberSL, LeeSW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature, 475:231–234. 2011.
207.
RassoolFV, GaymesTJ, OmidvarN, BradyN, BeurletS, PlaM, ReboulM, LeaN, ChomienneC, ThomasNS, MuftiGJ, PaduaRA. Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?Cancer Res, 67:8762–8771. 2007.
208.
RaviD, DasKC. Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage. Cancer Chemother Pharmacol, 54:449–458. 2004.
209.
ReddyMM, FernandesMS, SalgiaR, LevineRL, GriffinJD, SattlerM. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia, 25:281–289. 2011.
RheeSG, WooHA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H(2)O(2), and protein chaperones. Antioxid Redox Signal, 15:781–794. 2011.
212.
RobakT, WierzbowskaA. Current and emerging therapies for acute myeloid leukemia. Clin Ther 31 Pt, 2:2349–2370. 2009.
213.
RosatoRR, AlmenaraJA, GrantS. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res, 63:3637–3645. 2003.
214.
RosatoRR, AlmenaraJA, MaggioSC, CoeS, AtadjaP, DentP, GrantS. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther, 7:3285–3297. 2008.
215.
RuefliAA, AusserlechnerMJ, BernhardD, SuttonVR, TaintonKM, KoflerR, SmythMJ, JohnstoneRW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A, 98:10833–10838. 2001.
216.
RushworthSA, BowlesKM, MacEwanDJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res, 71:1999–2009. 2011.
217.
RushworthSA, BowlesKM, RaningaP, MacEwanDJ. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res, 70:2973–2983. 2010.
218.
RushworthSA, MacEwanDJ. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood, 111:3793–3801. 2008.
219.
RushworthSA, MacEwanDJ, O'ConnellMA. Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol, 181:6730–6737. 2008.
220.
SaitohM, NishitohH, FujiiM, TakedaK, TobiumeK, SawadaY, KawabataM, MiyazonoK, IchijoH. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J, 17:2596–2606. 1998.
221.
SallmyrA, FanJ, DattaK, KimKT, GrosuD, ShapiroP, SmallD, RassoolF. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood, 111:3173–3182. 2008.
222.
SattlerM, VermaS, ShrikhandeG, ByrneCH, PrideYB, WinklerT, GreenfieldEA, SalgiaR, GriffinJD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem, 275:24273–24278. 2000.
223.
SenturkerS, KarahalilB, InalM, YilmazH, MuslumanogluH, GedikogluG, DizdarogluM. Oxidative DNA base damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. FEBS Lett, 416:286–290. 1997.
224.
ServidaF, SoligoD, DeliaD, HendersonC, BrancoliniC, LombardiL, DeliliersGL. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia, 19:2324–2331. 2005.
225.
SgambatoA, CameriniA, PaniG, CangianoR, FaragliaB, BianchinoG, De BariB, GaleottiT, CittadiniA. Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer, 88:1956–1962. 2003.
226.
ShahNP, NicollJM, NagarB, GorreME, PaquetteRL, KuriyanJ, SawyersCL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117–125. 2002.
227.
ShanafeltTD, LeeYK, BoneND, StregeAK, NarayananVL, SausvilleEA, GeyerSM, KaufmannSH, KayNE. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood, 105:2099–2106. 2005.
228.
ShaoL, DiccianniMB, TanakaT, GribiR, YuAL, PullenJD, CamittaBM, YuJ. Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res, 61:7333–7338. 2001.
229.
ShenZX, ChenGQ, NiJH, LiXS, XiongSM, QiuQY, ZhuJ, TangW, SunGL, YangKQ, ChenY, ZhouL, FangZW, WangYT, MaJ, ZhangP, ZhangTD, ChenSJ, ChenZ, WangZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89:3354–3360. 1997.
230.
ShiJ, RossCR, LetoTL, BlechaF. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc Natl Acad Sci U S A, 93:6014–6018. 1996.
231.
SiesH. Glutathione and its role in cellular functions. Free Radic Biol Med, 27:916–921. 1999.
232.
SilvaA, GirioA, CebolaI, SantosCI, AntunesF, BarataJT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia, 25:960–967. 2011.
SoignetSL, FrankelSR, DouerD, TallmanMS, KantarjianH, CallejaE, StoneRM, KalaycioM, ScheinbergDA, SteinherzP, SieversEL, CoutreS, DahlbergS, EllisonR, WarrellRPJr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 19:3852–3860. 2001.
237.
StockerR, GlazerAN, AmesBN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A, 84:5918–5922. 1987.
238.
StockerR, YamamotoY, McDonaghAF, GlazerAN, AmesBN. Bilirubin is an antioxidant of possible physiological importance. Science, 235:1043–1046. 1987.
239.
StockwinLH, BumkeMA, YuSX, WebbSP, CollinsJR, HollingsheadMG, NewtonDL. Proteomic analysis identifies oxidative stress induction by adaphostin. Clin Cancer Res, 13:3667–3681. 2007.
240.
SusnowN, ZengL, MargineantuD, HockenberyDM. Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol, 19:42–49. 2009.
241.
SzczepanekJ, PogorzalaM, KonatkowskaB, JuraszewskaE, BadowskaW, OlejnikI, KuzmiczM, StanczakE, MalinowskaI, StefaniakJ, SobolG, SzczepanskiT, CzyzewskiK, WysockiM, StyczynskiJ. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res, 30:2119–2124. 2010.
242.
TakashimaY, HirotaK, NakamuraH, NakamuraT, AkiyamaK, ChengFS, MaedaM, YodoiJ. Differential expression of glutaredoxin and thioredoxin during monocytic differentiation. Immunol Lett, 68:397–401. 1999.
243.
TanakaK, FujimotoY, SuzukiM, SuzukiY, OhtakeT, SaitoH, KohgoY. PI3-kinase p85alpha is a target molecule of proline-rich antimicrobial peptide to suppress proliferation of ras-transformed cells. Jpn J Cancer Res, 92:959–967. 2001.
TrachoothamD, ZhangH, ZhangW, FengL, DuM, ZhouY, ChenZ, PelicanoH, PlunkettW, WierdaWG, KeatingMJ, HuangP. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood, 112:1912–1922. 2008.
247.
TrachoothamD, ZhouY, ZhangH, DemizuY, ChenZ, PelicanoH, ChiaoPJ, AchantaG, ArlinghausRB, LiuJ, HuangP. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 10:241–252. 2006.
248.
TsaiSY, SunNK, LuHP, ChengML, ChaoCC. Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma. Cancer Sci, 98:1206–1214. 2007.
UngerstedtJS, SowaY, XuWS, ShaoY, DokmanovicM, PerezG, NgoL, HolmgrenA, JiangX, MarksPA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A, 102:673–678. 2005.
251.
VieiraSA, DeiningerMW, SorourA, SinclairP, ForoniL, GoldmanJM, MeloJV. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer, 32:353–363. 2001.
252.
Vivas-MejiaPE, OzpolatB, ChenX, Lopez-BeresteinG. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer, 125:264–275. 2009.
253.
WallaceDC. Mitochondrial diseases in man and mouse. Science, 283:1482–1488. 1999.
254.
WangJ, LiL, CangH, ShiG, YiJ. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk Res, 32:429–436. 2008.
255.
WangX, ZhangJ, XuT. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol, 218:88–95. 2007.
256.
WenST, Van EttenRA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev, 11:2456–2467. 1997.
257.
WilliamsBL, SchreiberKL, ZhangW, WangeRL, SamelsonLE, LeibsonPJ, AbrahamRT. Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line. Mol Cell Biol, 18:1388–1399. 1998.
WuWS, WuJR, HuCT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev, 27:303–314. 2008.
260.
XuK, ThornalleyPJ. Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro. Biochem Pharmacol, 61:165–177. 2001.
261.
XuW, NgoL, PerezG, DokmanovicM, MarksPA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A, 103:15540–15545. 2006.
262.
XuX, ZhangXA, WangDW. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev, 63:597–609. 2011.
263.
YahataT, MugurumaY, YuminoS, ShengY, UnoT, MatsuzawaH, ItoM, KatoS, HottaT, AndoK. Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis. Stem Cells, 26:3228–3236. 2008.
264.
YahataT, TakanashiT, MugurumaY, IbrahimAA, MatsuzawaH, UnoT, ShengY, OnizukaM, ItoM, KatoS, AndoK. Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood, 118:2941–2950. 2011.
265.
YamaguchiS, SakuradaS, NagumoM. Role of intracellular SOD in protecting human leukemic and cancer cells against superoxide and radiation. Free Radic Biol Med, 17:389–395. 1994.
266.
YoshidaC, YoshidaF, SearsDE, HartSM, IkebeD, MutoA, BasuS, IgarashiK, MeloJV. Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood, 109:1211–1219. 2007.
267.
YuC, RahmaniM, ConradD, SublerM, DentP, GrantS. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 102:3765–3774. 2003.
268.
ZamockyM, FurtmullerPG, ObingerC. Evolution of catalases from bacteria to humans. Antioxid Redox Signal, 10:1527–1548. 2008.
269.
ZelenI, DjurdjevicP, PopovicS, StojanovicM, JakovljevicV, RadivojevicS, BaskicD, ArsenijevicN. Antioxidant enzymes activities and plasma levels of oxidative stress markers in B-chronic lymphocytic leukemia patients. J BUON, 15:330–336. 2010.
270.
ZhangH, TrachoothamD, LuW, CarewJ, GilesFJ, KeatingMJ, ArlinghausRB, HuangP. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia, 22:1191–1199. 2008.
271.
ZhangMJ, HoelzerD, HorowitzMM, GaleRP, MessererD, KleinJP, LofflerH, SobocinskiKA, ThielE, WeisdorfDJ. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med, 123:428–431. 1995.
272.
ZhangP, LiuB, KangSW, SeoMS, RheeSG, ObeidLM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem, 272:30615–30618. 1997.
273.
ZhangX, ShanP, AlamJ, FuXY, LeePJ. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J Biol Chem, 280:8714–8721. 2005.
274.
ZhangY. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res, 555:173–190. 2004.
275.
ZhangY, EmmanuelN, KambojG, ChenJ, ShurafaM, Van DykeDL, WiktorA, RowleyJD. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22)Genes Chromosomes Cancer, 40:365–370. 2004.
276.
ZhangY, TalalayP. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res, 54:1976s–1981s. 1994.
277.
ZhangY, TangL, GonzalezV. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther, 2:1045–1052. 2003.
278.
ZhangZ, BlakeDR, StevensCR, KanczlerJM, WinyardPG, SymonsMC, BenboubetraM, HarrisonR. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res, 28:151–164. 1998.
279.
ZhouFL, ZhangWG, WeiYC, MengS, BaiGG, WangBY, YangHY, TianW, MengX, ZhangH, ChenSP. Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem, 285:15010–15015. 2010.
280.
ZhouJ, BiC, CheongLL, MaharaS, LiuSC, TayKG, KohTL, YuQ, ChngWJ. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood, 118:2830–2839. 2011.
281.
ZhouY, HilemanEO, PlunkettW, KeatingMJ, HuangP. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood, 101:4098–4104. 2003.
282.
ZuoXL, ChenJM, ZhouX, LiXZ, MeiGY. Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biol Trace Elem Res, 114:41–53. 2006.
